Aeglea Biotherapeutics Stock News

Penny stocks to watch this week with news. The post 5 Top Penny Stocks To Watch With News Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

The Dow Jones tumbled by over 500 points on Friday. Investors, meanwhile, focused on some notable insider trades.

Aeglea (AGLE) announces a corporate restructuring plan to prioritize the development of AGLE-177 for patients living with homocystinuria. The company's current CEO resigns.

Aeglea BioTherapeutics (AGLE) seeks a nod for its lead candidate, pegzilarginase, for treating ARG1-D in the European Union. Stock surges post announcement.

Here's what you need to know about trading penny stocks on August 22nd The post Buying Penny Stocks Right Now? 3 to Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information |

Penny stocks with unusual options activity today. The post 4 Penny Stocks To Watch With Bullish Buys From Options Traders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStoc

Aeglea (AGLE) gets a Refusal to File letter from the FDA related to the biologics license application for pegzilarginase to treat arginase 1 deficiency. Stock down.

Aeglea (AGLE) delivered earnings and revenue surprises of -5.71% and 6.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Aeglea (AGLE) files a biologics license application to the FDA for pegzilarginase to treat arginase 1 deficiency. The company has requested the FDA to grant priority review to the BLA.

Aeglea BioTherapeutics (NASDAQ: AGLE ) reported its Q4 earnings results on Tuesday, March 8, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Aeglea BioTherapeutics missed estimated earnings by 6.9%, reporting … Full story available on Benzinga.com

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as…

Aeglea (AGLE) delivered earnings and revenue surprises of 3.12% and 18.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Aeglea BioTherapeutics <> is trading lower for the third straight session after announcing that Sara Brownstein, a Class I director of its Board, informed the company on

Aeglea BioTherapeutics (AGLE) withdraws its previously announced, proposed public offering

AUSTIN, Texas , Feb. 9, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE ), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock. Aeglea expects to grant the underwriters a 30-day option to purchase additional shares of common stock. All of the securities are being offered by Aeglea. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. JonesTrading Institutional Services LLC and LifeSci Capital LLC are acting as joint book-running managers in the offering. Aeglea intends to use the net proceeds from the offering, together with its existing cash resources, to fund its ongoing Biologics License Application submission activities for pegzilarginase and its potential commercialization in the United States , complete its ongoing Phase 1/2 clinical trial of AGLE-177 and prepare for a potential pivotal study in Homocystinuria, advance AGLE-325 for Cystinuria through IND-enabling studies, and the remainder to fund continued research and development, manufacturing, working capital …